Johnson & Johnson (JNJ)vsNektar Therapeutics (NKTR)
JNJ
Johnson & Johnson
$275.19
+1.53%
HEALTHCARE · Cap: $615.87B
NKTR
Nektar Therapeutics
$38.55
+1.53%
HEALTHCARE · Cap: $1.22B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 181869% more annual revenue ($99.33B vs $54.59M). JNJ leads profitability with a 16.2% profit margin vs -287.8%. NKTR appears more attractively valued with a PEG of 0.31. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
NKTR
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$275.19
$131.07 premium
Intrinsic value data unavailable for NKTR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Growing faster than its price suggests
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -53.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bull Case : NKTR
The strongest argument for NKTR centers on PEG Ratio, Price/Book, Debt/Equity. PEG of 0.31 suggests the stock is reasonably priced for its growth.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : NKTR
The primary concerns for NKTR are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
JNJ profiles as a mature stock while NKTR is a turnaround play — different risk/reward profiles.
NKTR carries more volatility with a beta of 1.27 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 33/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Nektar Therapeutics
HEALTHCARE · BIOTECHNOLOGY · USA
Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?